CD8A and immune system toxicity: Our results demonstrated that OsrHSA is equivalent to pHSA in terms of its effects on T cell proliferation, CD4+ and CD8+ T cells and cytokine levels, suggesting that there is no evident potential for immunotoxicity with OsrHSA treatment in PBMC.